Gyre Therapeutics, Inc. (GYRE) Investor Relations Documents

Gyre Therapeutics, Inc. (GYRE) investor relations documents from the company's IR site: 4 presentations, 11 press releases; latest deck 2026-06-01. Read in-app with summaries. First-party data.

Corporate Presentation June 2026: Gyre Therapeutics is a biopharmaceutical company focused on fibrosis, inflammatory diseases, and cancer, leveraging US-China operations for drug development.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-07Press releaseGyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
2026-07-16Press releaseGyre Therapeutics Appoints Three New Members to its Board of Directors
2026-06-01PresentationCorporate Presentation June 2026
2026-05-12Press releaseGyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosi
2026-05-07Press releaseGyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
2026-05-04Press releaseGyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Co
2026-03-17Press releaseGyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver
2026-03-12Press releaseGyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-03-02Press releaseGyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
2026-03-02PresentationGyre Therapeutics – Cullgen Acquisition Presentation
2026-01-27PresentationCorporate Presentation January 2026
2026-01-05Press releaseGyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility f
Press releaseGyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Up
2025-05-22PresentationHydronidone Phase 3 Results Review May 22, 2025
Press releaseGyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

GYRE overview · GYRE earnings · GYRE financials · GYRE KPIs · GYRE documents · GYRE ownership · GYRE peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.